Researchers at the Medical University of South Carolina’s Center for Biomedical Imaging have engineered a lipid nanocarrier capable of carrying a concentrated dose of the chemotherapy drug TMZ directly into the cells of aggressive glioblastoma brain tumors.
“We take advantage of the tumor’s natural environment as well as the cellular expression,” Ann-Marie Broome, PhD, director of molecular imaging and lead author of a research paper describing the work, told the online nanotech publication AZoNano.
Broome adds that many past treatments have likely failed “because you have to take into account the immune system, the local environment and the cells themselves—all three of these are important considerations.”
Read the AZoNano news report:
Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.